Adonis | Latest News & Updates - May 01, 2025 Release
Eli Lilly has sued Adonis Health and three other telehealth companies for allegedly misleading consumers and illegally prescribing compounded versions of its GLP-1 drugs...
Brought to you by RivalSense - an AI tool for monitoring any company.
RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡


Adonis
🌎 adonis.ioAdonis is a Revenue Intelligence and Automation Platform designed specifically for the healthcare industry. It addresses operational challenges that hinder effective revenue cycle management (RCM), helping healthcare providers recover a significant portion of the revenue they are owed. Utilizing data science and AI technology, Adonis offers solutions that enhance billing processes, automate workflows, and provide actionable insights to improve financial outcomes for healthcare organizations.
Adonis - Latest News and Updates
- Eli Lilly has sued Adonis Health and three other telehealth companies for allegedly misleading consumers and illegally prescribing compounded versions of its GLP-1 drugs.
- U.S. Dermatology Partners selects Adonis to enhance revenue growth and prior authorization processes.
- Adonis CEO Akash Magoon and Head of Partnerships Doug Pickett will attend the Elion AI RCM Summit in La Jolla on April 28-30 to discuss AI's impact on healthcare and revenue cycle.
- Doug Pickett, Head of Sales at Adonis, reported that a partner used real-time alerting to quickly adapt to a major payer's updated prior authorization policy, preventing revenue loss.
- Adonis is currently seeking a Customer Success Manager - Deployments in the United States.
- On April 24, Adonis hosted a live conversation with Sri Chandrasekar, Managing Partner at Point72 Ventures, and CEO Akash Magoon at their New York City headquarters.
Sign up to receive regular updates
If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.
